Rallybio CFO shifts to part-time ahead of merger

Rallybio’s CFO will shift to part-time status with a fixed salary and no bonus until his role ends at the closing of the pending Avenzo merger.

Rhea-AI Filing Summary

Rallybio Corp (RLYB) reported a change in the work arrangement of its Chief Financial Officer, Jonathan LieberSeptember 15, 2026base salary of $420,000Avenzo Therapeutics, Inc.May 31, 2026

Filing Explained

The September 15 change preserves CFO authority but removes annual-bonus eligibility until employment ends at the Avenzo closing.

Rallybio discloses that CFO Jonathan Lieber will move to part-time status on September 15, 2026, while remaining its CFO and principal financial officer with the same duties and authority.

Under the employment side letter, he will receive a base salary of $420,000 and will not receive an annual bonus for 2026 or any later year in which he remains employed.

His employment is scheduled to terminate when Rallybio’s pending business combination with Avenzo Therapeutics closes, rather than on the part-time transition date.

At termination, the filing states that severance will be paid under his existing employment agreement and its second amendment; the filing does not state the severance amount.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Effective date of part-time status: September 15, 2026 Base salary: $420,000 Merger agreement date: May 31, 2026 +1 more

4 metrics

Effective date of part-time status September 15, 2026 Date when the CFO transitions to part-time employment

Base salary $420,000 Annual base salary for Jonathan Lieber after the Employment Transition Date

Merger agreement date May 31, 2026 Date of the Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc.

Employment Side Letter date September 8, 2026 Date of the Employment Side Letter with Jonathan Lieber

Key Terms

Emerging growth company, Principal Financial Officer, Agreement and Plan of Merger and Reorganization, severance payments, +2 more

6 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Principal Financial Officer financial

"remain Rallybio’s Chief Financial Officer and Principal Financial Officer"

The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.

Agreement and Plan of Merger and Reorganization regulatory

"pending business combination with Avenzo Therapeutics, Inc. (Avenzo) pursuant to the Agreement and Plan of Merger and Reorganization"

severance payments financial

"Upon his termination, Mr. Lieber will be entitled to severance payments as set forth in his Employment Agreement"

Payments made to employees after their job ends, typically as a lump sum or continued pay and benefits for a limited period. Investors watch severance payments because they are a predictable one-time cost or ongoing liability for the company—like an exit fee when someone leaves a club—and sizable payouts can reduce profits, affect cash flow, or signal larger restructuring costs ahead.

Employment Side Letter regulatory

"The foregoing description of the Employment Side Letter does not purport to be complete"

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did Rallybio (RLYB) announce regarding its Chief Financial Officer?

Rallybio announced that Jonathan Lieberpart-time employment

What compensation will the RLYB CFO receive after moving to part-time status?

After September 15, 2026, Jonathan Lieber will receive a base salary of $420,000annual bonus for 2026

When will the Rallybio (RLYB) CFO’s employment terminate?

Jonathan Lieber’s employment is scheduled to terminate upon the closing of Rallybio’s pending business combination with Avenzo Therapeutics, Inc.

Will the RLYB CFO receive severance when his employment ends?

Yes. Upon termination of his employment, Jonathan Lieber will be entitled to severance payments

What agreement governs the Rallybio (RLYB) CFO’s new part-time terms?

The new part-time arrangement is governed by an Employment Side Letter

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:31 PM Accepted by SEC EDGAR 09/09/2026 - 04:30 PM Learn about SEC filing dates

Rallybio Corp NASDAQ PO Box 325 false 0001739410 0001739410 2026-09-08 2026-09-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2026

RALLYBIO CORPORATION

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-40693		85-1083789
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

PO Box No. 325 East Berlin, Connecticut		06023
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 203 859-3820

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		RLYB		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 8, 2026, Rallybio Corporation (Rallybio) announced that Jonathan Lieber, Rallybio’s Chief Financial Officer, will transition to part-time employment status effective September 15, 2026 (the Employment Transition Date), but will remain Rallybio’s Chief Financial Officer and Principal Financial Officer and continue to have the same duties and authority following the Employment Transition Date.

In connection with Mr. Lieber’s employment transition, he entered into an agreement (the Employment Side Letter) with Rallybio and Rallybio, LLC pursuant to which, following the Employment Transition Date, he will receive a base salary of $420,000 and be entitled to participate in Rallybio’s benefit plans, but will not be entitled to receive an annual bonus for 2026 or any subsequent year during which he is employed. Mr. Lieber’s employment will terminate upon the closing of Rallybio’s pending business combination with Avenzo Therapeutics, Inc. (Avenzo) pursuant to the Agreement and Plan of Merger and Reorganization, dated May 31, 2026, among Rallybio, Avenzo and a wholly-owned subsidiary of Rallybio, unless earlier terminated by Mr. Lieber or Rallybio. Upon his termination, Mr. Lieber will be entitled to severance payments as set forth in his Employment Agreement with Rallybio, dated February 1, 2023, and the Second Amendment to his Employment Agreement, which were included as Exhibit 10.24 to Rallybio’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 2, 2023 and Exhibit 10.8 to Rallybio’s Current Report on Form 8-K filed with the SEC on June 1, 2026, respectively.

The foregoing description of the Employment Side Letter does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the Employment Side Letter, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Exhibit Description
10.1		Employment Side Letter, by and between Rallybio Corporation, Rallybio, LLC and Jonathan Lieber, dated September 8, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						RALLYBIO CORPORATION
Date: September 9, 2026				By:		/s/ Jonathan I. Lieber
						Jonathan I. Lieber Chief Financial Officer

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 EX-10.1 17.4 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB